Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir

被引：0
作者：
Alessio Aghemo
Yves Horsmans
Stefan Bourgeois
Mark Bondin
Michael Gschwantler
Harald Hofer
Nasser Semmo
Francesco Negro
Zhenzhen Zhang
John Marcinak
Ella Veitsman
Rawi Hazzan
Konstantinos Mimidis
Ioannis Goulis
Nuno Marques
Robert Flisiak
Wlodzimierz Mazur
Carlos Roncero
Fiona Marra
Georges Philippe Pageaux
Tarik Asselah
Pietro Lampertico
机构：
[1] Humanitas University,Department of Biomedical Sciences
[2] Cliniques Universitaires Saint-Luc,Department of Internal Medicine IV
[3] UCL,Department of Internal Medicine, Gastroenterology and Hepatology
[4] Stuivenberg ZNA,Department of BioMedical Research, Hepatology
[5] AbbVie Inc,Division of Gastroenterology and Hepatology
[6] Wilhelminenspital,Liver Unit
[7] and Sigmund Freud University,First Department of Internal Medicine
[8] Klinikum Wels-Grieskirchen,4th Department of Internal Medicine
[9] Inselspital,Infectious Diseases Service
[10] University of Bern,Department of Infectious Diseases and Hepatology
[11] University Hospital,Clinical Department of Infectious Diseases
[12] Rambam Health Care Campus,Psychiatry Service
[13] Emek Medical Center,Hepatology Drug Interactions Group
[14] Democritus University of Thrace Medical School,Département Hépato
[15] Aristotle University of Thessaloniki,Gastro
[16] Hospital Garcia de Orta EPE,Entérologie
[17] Medical University of Białystok,Department of Hepatology
[18] Medical University of Silesia,Division of Internal Medicine and Hepatology, Department of Gastroenterology
[19] University of Salamanca Health Care Complex,Institute of Biomedicine and School of Medicine
[20] University of Liverpool,Division of Clinical Pathology
[21] Centre Hospitalier Universitaire (CHU) de Montpellier,undefined
[22] Hopital Beaujon,undefined
[23] AP-HP,undefined
[24] Paris University and INSERM UMR 1149,undefined
[25] Foundation IRCCS Ca’ Granda,undefined
[26] Ospedale Maggiore Policlinico,undefined
[27] Policlinico-Division of Gastroenterology and Hepatology-CRC ‘AM and A Migliavacca’ Centre for Liver Disease,undefined
[28] University of Milan,undefined
[29] Humanitas Research Hospital IRCCS,undefined
[30] University of Salamanca,undefined
[31] University Hospital,undefined
来源：
Infectious Diseases and Therapy | 2021年 / 10卷
关键词：
Alcohol use disorder; Health-related quality of life; Hepatitis C; Illicit drugs; Psychiatric disorders;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2203 / 2222
页数：19
相关论文
共 183 条
[1]  
Asselah T(2018)Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure? Liver Int 38 7-13
[2]  
Marcellin P(2017)Current therapy for chronic hepatitis C: the role of direct-acting antivirals Antiviral Res 142 83-122
[3]  
Schinazi RF(2020)People with hepatitis C who inject drugs—underserved, not undeserving N Engl J Med 383 608-611
[4]  
Li G(2018)The micro-elimination approach to eliminating hepatitis C: strategic and operational considerations Semin Liver Dis 38 181-192
[5]  
De Clercq E(2018)Treatment of hepatitis C: the use of the new pangenotypic direct-acting antivirals in "special populations" Liver Int 38 28-33
[6]  
Dore GJ(2013)Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals Hepatology 58 1598-1609
[7]  
Trooskin S(2018)Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study Lancet Infect Dis 18 215-224
[8]  
Lazarus JV(2019)The distribution and socioeconomic burden of Hepatitis C virus in South Australia: a cross-sectional study 2010–2016 BMC Public Health 19 527-662
[9]  
Safreed-Harmon K(2014)Reducing barriers to hepatitis C treatment among drug users: an integrated hepatitis C peer education and support program J Health Care Poor Underserved 25 652-511
[10]  
Thursz MR(2018)EASL recommendations on treatment of hepatitis C 2018 J Hepatol 69 461-426
12345678910